Ahmed Enayetallah

Ahmed Enayetallah, M.D., Ph.D., is Head of Development at BlueRock Therapeutics. With more than 20 years of experience, Ahmed brings in-depth expertise across the drug research and development spectrum. Prior to BlueRock, Ahmed was an Executive Medical Director and Group Lead, Neurology and Ophthalmology at AstraZeneca’s Alexion Rare Disease Unit where he led and oversaw the execution of six clinical-stage rare disease programs, including Soliris & Ultomiris in GBS, gMG, and NMOSD. Ahmed has also held roles in early and late-stage programs at Amgen, Biogen, and Pfizer. Ahmed earned his medical degree at the University of Cairo School of Medicine with residency training in general surgery. Ahmed holds a Ph.D. in Pharmacology and Toxicology from the University of Connecticut.